Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification.

Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification.

The HER3 receptor is implicated in the progression of various cancers as well as in resistance to several currently used drugs, and is hence a potential target for development of new therapies. We have previously generated Affibody molecules that inhibit heregulin-induced signaling of the HER3 pathw...

Full description

Bibliographic Details
Main Authors: Magdalena Malm, Nina Kronqvist, Hanna Lindberg, Lindvi Gudmundsdotter, Tarek Bass, Fredrik Y Frejd, Ingmarie Höidén-Guthenberg, Zohreh Varasteh, Anna Orlova, Vladimir Tolmachev, Stefan Ståhl, John Löfblom
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3651084?pdf=render

Internet

http://europepmc.org/articles/PMC3651084?pdf=render

Similar Items